Providing Today's Patients with Medicines of the Future.
Staff
2017-2019 Net Profit CAGR
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions
On May 21, 2026, Simcere Zaiming announced that SIM0532, a pan-RAS-targeted investigational anti-tumor drug independently developed by the company, ha...
May 6, 2026, Simcere Zaiming announces today that SIM0613 for Injection, an LRRC15-targeting antibody-drug conjugate (ADC) independently developed by ...
April 8 2026, Simcere Zaiming announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SIM0505, for the treat...
March 30, 2026 — Simcere Pharmaceutical Group Limited (2096.HK) announced that Phase III results from the RADIANT-AD study of rademikibart, an investi...
Telephone: 025-85566666 Fax：025-85262330
Address: 699-18 Xuanwu Avenue Nanjing China
Zipcode：210042
Fax：025-85471729
Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345 Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate) ? Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.